Newswise — PHILADELPHIA—(March 22, 2016)—The Wistar Institute is pleased to welcome James W. Lovett to its Board of Trustees. Lovett served for 14 years as corporate senior vice president, general counsel and secretary of Covance Inc. (NYSE: CVD), a global drug development services company based in Princeton, N.J. At Covance, Lovett was responsible for global legal affairs, corporate governance, government relations, and corporate securities. He also led three different Covance operating business teams during his tenure. Lovett played an important role in Covance’s Feb. 2015 sale to LabCorp, which merged two major life sciences companies.
Lovett has broad life sciences industry experience having served on the boards of BioClinica, Inc., the National Association for Biomedical Research, and the Pennsylvania Society for Biomedical Research as board chairman. Mr. Lovett currently is vice-chairman of the Board of Trustees of Scholar Academies, a nonprofit charter school management organization.
Prior to Covance, Inc., Lovett was associate general counsel of FMC Corporation (NYSE: FMC), a diversified manufacturing conglomerate, a partner at McDermott, Will & Emery, in Chicago, and law clerk to the Honorable Boyce F. Martin, Jr., on the U.S. Court of Appeals for the Sixth Circuit.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
RSS